157 related articles for article (PubMed ID: 25000332)
1. Benchmark dose and the three Rs. Part I. Getting more information from the same number of animals.
Slob W
Crit Rev Toxicol; 2014 Aug; 44(7):557-67. PubMed ID: 25000332
[TBL] [Abstract][Full Text] [Related]
2. Benchmark dose and the three Rs. Part II. Consequences for study design and animal use.
Slob W
Crit Rev Toxicol; 2014 Aug; 44(7):568-80. PubMed ID: 25000331
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the benchmark dose for point of departure determination for a variety of chemical classes in applied regulatory settings.
Izadi H; Grundy JE; Bose R
Risk Anal; 2012 May; 32(5):830-5. PubMed ID: 22126138
[TBL] [Abstract][Full Text] [Related]
4. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
Zhu Y; Wang T; Jelsovsky JZ
Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
[TBL] [Abstract][Full Text] [Related]
5. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach.
Bokkers BG; Slob W
Crit Rev Toxicol; 2007 Jun; 37(5):355-73. PubMed ID: 17612951
[TBL] [Abstract][Full Text] [Related]
6. Does EU legislation allow the use of the Benchmark Dose (BMD) approach for risk assessment?
Brandon EF; Bulder AS; van Engelen JG; Mahieu CM; Mennes WC; Pronk ME; Rietveld AG; van de Ven BM; Ten Voorde SE; Wolterink G; Slob W; Zeilmaker MJ; Bessems JG
Regul Toxicol Pharmacol; 2013 Nov; 67(2):182-8. PubMed ID: 23871753
[TBL] [Abstract][Full Text] [Related]
7. Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDS) version 2.1.1.
Davis JA; Gift JS; Zhao QJ
Toxicol Appl Pharmacol; 2011 Jul; 254(2):181-91. PubMed ID: 21034758
[TBL] [Abstract][Full Text] [Related]
8. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
Filipsson AF; Sand S; Nilsson J; Victorin K
Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
[TBL] [Abstract][Full Text] [Related]
9. The current state of knowledge on the use of the benchmark dose concept in risk assessment.
Sand S; Victorin K; Filipsson AF
J Appl Toxicol; 2008 May; 28(4):405-21. PubMed ID: 17879232
[TBL] [Abstract][Full Text] [Related]
10. Benchmark dose approaches in chemical health risk assessment in relation to number and distress of laboratory animals.
Oberg M
Regul Toxicol Pharmacol; 2010 Dec; 58(3):451-4. PubMed ID: 20800084
[TBL] [Abstract][Full Text] [Related]
11. A benchmark dose analysis for sodium monofluoroacetate (1080) using dichotomous toxicity data.
Foronda NM; Fowles J; Smith N; Taylor M; Temple W
Regul Toxicol Pharmacol; 2007 Feb; 47(1):84-9. PubMed ID: 16965845
[TBL] [Abstract][Full Text] [Related]
12. Benchmark Dose Workshop: criteria for use of a benchmark dose to estimate a reference dose.
Barnes DG; Daston GP; Evans JS; Jarabek AM; Kavlock RJ; Kimmel CA; Park C; Spitzer HL
Regul Toxicol Pharmacol; 1995 Apr; 21(2):296-306. PubMed ID: 7644719
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the lower limit of benchmark dose confidence interval with no-observed-adverse-effect level by applying four different software for tumorigenicity testing of pesticides in Japan.
Yasuhiko Y; Ishigami M; Machino S; Fujii T; Aoki M; Irie F; Kanda Y; Yoshida M
Regul Toxicol Pharmacol; 2022 Aug; 133():105201. PubMed ID: 35691450
[TBL] [Abstract][Full Text] [Related]
14. Current modeling practice may lead to falsely high benchmark dose estimates.
Ringblom J; Johanson G; Öberg M
Regul Toxicol Pharmacol; 2014 Jul; 69(2):171-7. PubMed ID: 24662478
[TBL] [Abstract][Full Text] [Related]
15. Benchmark dose calculation for ordered categorical responses.
Chen CC; Chen JJ
Risk Anal; 2014 Aug; 34(8):1435-47. PubMed ID: 24444309
[TBL] [Abstract][Full Text] [Related]
16. Application of benchmark dose for occupational epidemiology in lead exposure.
Lin T; Xiao-Ting L; Ai G; Qiu-Ying L; Tai-Yi J
Toxicol Mech Methods; 2008; 18(4):363-7. PubMed ID: 20020903
[TBL] [Abstract][Full Text] [Related]
17. Use of benchmark dose and meta-analysis to determine the most sensitive endpoint for risk assessment for dimethoate.
Reiss R; Gaylor D
Regul Toxicol Pharmacol; 2005 Oct; 43(1):55-65. PubMed ID: 16099569
[TBL] [Abstract][Full Text] [Related]
18. Identification of a critical dose level for risk assessment: developments in benchmark dose analysis of continuous endpoints.
Sand S; von Rosen D; Victorin K; Filipsson AF
Toxicol Sci; 2006 Mar; 90(1):241-51. PubMed ID: 16322076
[TBL] [Abstract][Full Text] [Related]
19. A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints.
Slob W; Moerbeek M; Rauniomaa E; Piersma AH
Toxicol Sci; 2005 Mar; 84(1):167-85. PubMed ID: 15483190
[TBL] [Abstract][Full Text] [Related]
20. The use of myocardial and testicular end points as a basis for estimating a proposed tolerable daily intake for sodium monofluoroacetate (1080).
Foronda NM; Fowles J; Smith N; Taylor M; Temple W; Darlington C
Regul Toxicol Pharmacol; 2007 Feb; 47(1):29-36. PubMed ID: 17030370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
